Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiestrogens: structure-activity relationships and use in breast cancer treatment.

Journal of molecular endocrinology - 1 Jan 2017

Traboulsi T, El Ezzy M, Gleason J L, Mader S

Abstract excerpt

About 70% of breast tumors express estrogen receptor alpha (ERα), which mediates the proliferative effects of estrogens on breast epithelial cells, and are candidates for treatment with antiestrogens, steroidal or non-steroidal molecules designed to compete with estrogens and antagonize ERs. The variable patterns of activity of antiestrogens (AEs) in estrogen target tissues and the lack of systematic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Clinical Trials as Topic
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Antagonists

Share to Estrogen Receptor alpha

Share to Molecular Conformation

Share to Receptors, Estrogen

Share to Selective Estrogen Receptor Modulators

Source

Open in PubMed Open full text

Identifiers

PMID: 27729460
DOI: 10.1530/JME-16-0024
PMCID: PMC5148801

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiestrogens: structure-activity relationships and use in breast cancer treatment.PMID 27729460Read ↗

Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.Semantic proximity Read ↗

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goalsSemantic proximity Read ↗

Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.Semantic proximity Read ↗

Estrogen receptors (ER<sub>α</sub>versus ER<sub>β</sub>): friends or foes in human biology?Semantic proximity Read ↗

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.Semantic proximity Read ↗

Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In VivoSemantic proximity Read ↗

Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor SuppressorSemantic proximity Read ↗

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.Semantic proximity Read ↗

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Semantic proximity Read ↗

Oral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast CancerSemantic proximity Read ↗

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.Semantic proximity Read ↗

Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.